Phase II Clinical Study of Concurrent Pazopanib for Non-metastatic Sarcoma Patients to be Treated With Radiotherapy, Localized in the Extremities, Trunk and Chest Wall or the Head and Neck Region (PASART-2)
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2018
At a glance
- Drugs Pazopanib (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms PASART-2
- 26 Sep 2017 Planned number of patients changed from 50 to 35.
- 26 Sep 2017 Planned End Date changed from 1 Apr 2020 to 1 Apr 2021.
- 26 Sep 2017 Planned primary completion date changed from 1 Jan 2020 to 1 Jan 2021.